Kipp Weiskopf, M.D., Ph.D.

Kipp Weiskopf, M.D., Ph.D. has a diverse work experience. Kipp started their career as an Undergraduate Research Program (URP) Participant at Cold Spring Harbor Laboratory in 2006. Kipp then worked as an Honors Thesis Student at Amherst College in 2006-2007. In 2007, they were a Churchill Scholar at the University of Cambridge. Following that, they joined Stanford University School of Medicine as a Student in the Medical Scientist Training Program from 2008 to 2016 under the guidance of Dr. Irving L. Weissman. In 2015, they co-founded ALX Oncology and served as a Scientific Advisory Board Member. In 2016, they became a Resident Physician in Internal Medicine at Brigham and Women's Hospital, where they worked until 2018. Kipp then joined Dana-Farber Cancer Institute as a Hematology & Oncology Fellow in 2018. In 2019, they became a Valhalla Whitehead Fellow at the Whitehead Institute. Most recently, in 2022, they co-founded DEM Biopharma, Inc., where they currently serve as the Co-Founder and Scientific Advisory Board Co-Chair.

Kipp Weiskopf, M.D., Ph.D. completed their Bachelor of Arts (BA) degree in Biology at Amherst College from 2003 to 2007. Following this, they pursued a Master of Philosophy (MPhil) degree in Biological Sciences (Genetics) at the University of Cambridge from 2007 to 2008. Kipp then enrolled in Stanford University School of Medicine and earned their M.D./Ph.D. degree from 2008 to 2016. However, the field of study for their M.D./Ph.D. program was not specified.